Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.

Slides:



Advertisements
Similar presentations
POSTER 82 CXCR4 using HIV-1 strains more abundant in PBMC than in plasma Chris Verhofstede 1 *, Linos Vandekerckhove 2, Veerle van Eygen 3, Kenny Dauwe.
Advertisements

Purging the HIV-1 Reservoir Through the Disruption of the PD-1 Pathway
Measuring the latent HIV Reservoir
Vaccine potential of dendritic cells pulsed with autologous virus in anti-HIV immune response Prof. Dr. Alberto José da Silva Duarte DERMATOLOGY DEPARTMENT.
Interactive Workshop “HIV Cure 101”: Challenges in identifying and targeting the HIV reservoir Sarah Palmer Centre for Virus Research Westmead Millennium.
HIV 101 Review Evaluation Center for HIV and Oral Health Boston University School of Public Health Health & Disability Working Group.
Prof. Fatma Amer Medical Microbiology and Immunology, ZAGAZIG FACULTY OF Medicine, Egypt President of ISC/HWG President of ArAPUA In the Era of Direct.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
BY: SHAN AND BITA. Background: MIF= cytokine macrophage migration inhibitory factor gp120= HIV-1 envelop glycoprotein p24= HIV-1 antigen PBMCS= peripheral.
Current HIV basic science research topics. Toddler "Functionally Cured" of HIV Infection- “the Mississippi Baby” First well-documented case of an HIV.
Measuring the latent HIV Reservoir
HIV and AIDS. Immune System Overview HIV lives in these cells.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Novel strategies for prevention and treatment of HIV infection Prasit Faipenkhong Pairoaj Vonghathaipaisarn Rodjana Chunhabundit Zhang Jianjun.
HIV, CD4, and More Karen Hutcherson Jenn Mann Elizabeth McCauley Michael Powers Courtney Wilson.
Acute HIV Infection Translating Pathogenesis into Opportunity Eric S. Rosenberg, M.D. Associate Professor of Medicine Massachusetts General Hospital Harvard.
Eric S. Rosenberg, M.D. Associate Professor of Medicine Massachusetts General Hospital Harvard Medical School
Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
AIDS supplement. History of HIV Originated in Africa in the late 1950’s Originally found in nonhuman primates and may have mutated First documented in.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
HIV Cellular Pathogenesis III
DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.
Conclusions Results show that the mutation at the N-linked glycosylation site N276D has a distinct influence on sensitivity to the HJ16 CD4bs neutralizing.
CCR5 Monoclonal Antibody PRO 140 Inhibited HIV-1 Resistant to Maraviroc, a Small Molecule CCR5 Antagonist Andre J Marozsan Progenics Pharmaceuticals, Inc.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Characterization of persistent HIV-1 in a broad spectrum of CD4 + T-cells isolated from peripheral blood, bone marrow, lymphoid tissue and gut associated.
1 Modelling the interactions between HIV and the immune system in hmans R. Ouifki and D. Mbabazi 10/21/2015AIMS.
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
Detecting Infectious HIV in Human Milk Miles W. Cloyd, Ph.D. Professor Department of Microbiology & Immunology University of Texas Medical Branch Galveston,
Anti-HIV Antibody Responses Reflect the Quantifiable HIV Reservoir Size Sulggi Lee, M.D., Ph.D. Assistant Professor of Medicine University of California,
HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to.
11 NAPWA Symposium 6 th IAS Meeting An HIV-based Lentiviral Vector Vaccine Achieves Functional Cure Post-challenge in a Subset of Vaccinated Macaques Dr.
Functional cure after long term HAART initiated during early HIV infection - a case study. van Lunzen J. 1,2, Schulze zur Wiesch J. 1,2, Schumacher U.
LOWERING THE DETECTION LIMITS OF HIV-1 VIRAL LOAD USING REAL-TIME IMMUNO-PCR FOR HIV-1 P24 ANTIGEN Niel T. Constantine, Ph.D., Daniel Edelman, M.S., Janet.
HIV Cellular Pathogenesis III Benhur Lee, M.D.. Adult v. infant (IgG v. IgA) CTL response (MHC tetramers) p24 antigenimia Ab response Viral load.
Active B19 virions production in hepatoblastoma and hepatocarcinoma cell lines: amplification and genomic stability. Op de beeck A. 1, Draps M.-L. 1, Baurin.
What are possible biomarkers for cure-related interventions ? Lars Ostergaard, MD, Ph.D., DMSc Prof/Head Dept of infectious diseases Aarhus.
Regulatory T cell abnormalities associated with aberrant CD4+ T-cell responses in HIV+ patients with immune reconstitution disease (IRD) Nabila SEDDIKI.
Liposomal Transfection of Dendritic Cells with gag mRNA Stimulates HIV-1 Specific Immune Responses Winni De Haes 1, Charlotte Pollard 1,4,Céline Merlin.
professor in microbiology
Blood Tests (“Labs”) 1. “Labs” Regular blood tests are a crucial part of HIV health care. They are often referred to as “bloods” or “labs” Several important.
HIV: Science, Sex and Society. Lecture 1. Mechanisms of viral persistence in the face of antiviral therapy. Mario Stevenson, Ph.D Department of Medicine.
Robert F. Siliciano, MD, PhD Professor of Medicine The Johns Hopkins University School of Medicine Baltimore, Maryland Update on HIV Cure Research FORMATTED:
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
Immune reconstitution Anjie Zhen, PhD
Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.
Date of download: 5/28/2016 From: Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases Ann.
CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.
Cellular immune control of Human Immunodeficiency Virus (HIV) Dr. Ali Jalil Ali College of pharmacy.
Virology – Antivirals 2 JU- 2 nd Year Medical Students By Dr Hamed AlZoubi – Microbiology and Immunology Department – Mutah University. MBBS (J.U.S.T)
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Alexander Pasternak Laboratory of Experimental Virology, Department of Medical Microbiology Academic Medical Center of the University of Amsterdam Amsterdam,
Emory University School of Medicine Department of Medicine
Catherine K. Koofhethile 21st IAS July,2016 Durban, SA
Figure 1. CD11b+CD33+CD14+HLA-DR−/lo myeloid-derived suppressor cell expansion by human immunodeficiency virus.
Volume 36, Issue 3, Pages (March 2012)
Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications.
Volume 140, Issue 2, Pages e1 (February 2011)
The block-and-lock approach
Galectin-9 binding to Tim-3 renders activated human CD4+ T cells less susceptible to HIV-1 infection by Shokrollah Elahi, Toshiro Niki, Mitsuomi Hirashima,
Prevention of Genital Herpes Simplex Virus Type 1 and 2 Disease in Mice Immunized with a gD-Expressing Dominant-Negative Recombinant HSV-1  Richard Brans,
Volume 34, Issue 1, Pages (January 2011)
Volume 24, Issue 8, Pages (August 2018)
The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells  Juha Punnonen, MD, PhD, Hans Yssel, PhD,
Volume 36, Issue 3, Pages (March 2012)
IL-12 affects Dermatophagoides farinae–induced IL-4 production by T cells from pediatric patients with mite-sensitive asthma  Takeshi Noma, MD, PhD, Izumi.
Virus-specific T cell responses are detected in all MERS survivors.
Presentation transcript:

Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens 1, Derek Atkinson 1, Eric Florence 2, Anne Buvé 3, Guido Vanham 1,4. 1 Virology unit, Department of Microbiology, Institute of Tropical Medicine, Antwerp (ITMA), Antwerp, Belgium. 2 HIV/STD unit, Department of Clinical Sciences, ITMA, Antwerp, Belgium. 3 STI/HIV Epidemiology and Control Unit, Department of Microbiology, ITMA, Antwerp, Belgium 4 Department of Medicinal Chemistry, University of Antwerp (UA); Faculty of Medicine and Pharmacy, Free University of Brussels (VUB) and Department of Gynecology and Obstetrics, Catholic University of Leuven (KUL), Belgium. Institute of Tropical Medicine, Antwerp Nationalestraat 155, B-2000 Antwerp, Belgium Tel Fax Abstract Background: So far highly active antiretroviral treatment (HAART) has not resulted in “cure” of HIV infection mainly because of latent virus reservoirs. Cessation of HAART typically results in viral rebound within days or weeks after treatment interruption. We have defined 4 patients who were treated for progressive HIV infection, but spontaneously controlled their VL for at least 6 months after cessation of HAART. We labeled these patients “secondary controllers” (SC). We hypothesized that the combined selection pressure of HAART and immunity had resulted in the induction of T-cell responses that prevent the archived provirus from growing out after treatment interruption. Here we present immune characteristics of these patients. Methods: We compared the SC with 4 control groups (of 4 patients each) including elite controllers (EC); patients under HAART; treatment naïve patients; and non-controllers. All patients were matched on % CD4 T-cells. Proviral load, intracellular unspliced and multiple spliced HIV mRNA in CD4 T-cells was measured by real-time PCR. Magnitude of T cell response against HIV was measured using IFN-  ELISPOT. Neutralizing activity of IgG was measured using TZMbl assay. The capacity to prevent infection by CD8+ T-cells was measured using a viral inhibition assay. Purified CD4+ T-cells were infected at MOI 10-3 with labstrains or autologous virus. Four hours after infection autologous CD8+ T-cells were added. P24 was monitored every 3 days, for 14 days. Results: Proviral load in SC and EC was much lower compared to the other groups and correlated with the amount of unspliced and multiple spliced mRNA. There was no difference between the groups in the magnitude of induced HIV-specific responses. However, there was a significant difference in the capacity of CD8+ T-cells to inhibit infection. CD8+ T-cells from all EC and SC could inhibit infection of CD4+ T-cells while those from others could not. Broad cross neutralizing antibodies were lacking in all patients. However, in contrast to the control patients, SC showed neutralization against autologous virus. Conclusion: SC had a normal disease progression before starting HAART but behave like EC after cessation of HAART. Low intracellular HIV DNA and RNA, together with strong virus inhibitory capacity are the most discriminating parameter of controllers versus non-controllers. These findings should be taken into account when designing and evaluating new immuno-therapeutic strategies. Patient Characteristics at enrolment of study GroupPatientHIV-1 subtypesexoriginageYears since HIV diagnosis Days on HAART Viral load (copies/ml) CD4 T cell count (cells/µl) SC P1BMBelgium <50250 P2DFBelgium < P3BMVenezuela364Unknown<50244 P4A1MBelgium < EC P5BMBelgium3670<50633 P6BMBelgium62130<50614 P7BMBelgium6190<50437 P8BMBelgium5990<50675 SNC P9DFCongo P10BMBelgium P11BMBelgium P12BFBelgium TN P13BMBelgium P14BMBelgium P15BMBrazil P16BMBelgium HAART P17CRF02_AGFBelgium <50707 P18BMBelgium <50973 P19BMBelgium <50806 P20BMBelgium <50438 Results: 1) Magnitude and breadth2) Virus inhibition assay3) Autologous neutralization4) Real time PCR Materials and methods Blood HIV-1 Donor plasma PBMC Isolation IgG Isolation total RNA Stimulation peptides Stimulation bispecific monoclonal AB Neutralization assay against autologous gp160 (result 3) Real time PCR for ribosomal, unspliced and multiple spliced RNA (Result 4) Real time PCR for proviral DNA and beta actin (Result 4) Virus inhibition assay (Result 2) ELISPOT (Result 1) PBMC from different patient groups were stimulated with peptide pools encoding the whole HIV genome. A)Represented the mean number of peptide pools inducing pos ELISPOT responses B)The mean number of IFN-  spot forming cells per million PBMC Purified CD4+ T-cells from SC (A) and from EC (B) were infected with different virus isolates and cultured in the absence or presence of CD8+ T-cells (1:1 ratio). On day 13 the ratio of p24 production in the supernatant of cultures with CD8+ T-cells and without CD8+ T-cells was calculated and the % inhibition of viral production is represented. Pseudoviral constructs were generated from the plasma samples. The same plasma was also used to purify IgG that was used in the PV-TZMbl neutralization assay to look for autologous neutralization. This assay was performed for SC (A), SNC (B), TN (C) and HAART patients (D). Percent neutralization is shown over a concentration range of individual patient IgG. Each patient is represented by one symbol. Boston, – CROI – 18th Conf on Retrovir & Opport Infect